Skip to main content

Table 5 Safety of IPTsc during intervention period

From: Efficacy and safety of intermittent preventive treatment for malaria in schoolchildren: a systematic review

Author (year) Study site Drug regime No of children Adverse events Observation
Dicko [23] Kambila SP (bimonthly) 61 No severe adverse event No data available
   Control 90
Clarke [24] Bondo SP + AQ (four-monthly) 2604 19 (0.79 %) severe adverse events (problems of balance, dizziness, feeling faint, nausea or vomiting)
6 (0.23 %) adverse events graded as moderate
49 (1.9 %) mild events (nausea, headache, prurititis)
Mild events were more frequent among children receiving active drugs than among controls
   Placebo 2302 4 (0.17 %) severe adverse events (problems of balance, dizziness, feeling faint, nausea or vomiting and one severe skin reaction)
7 (0.30 %) moderate adverse events
33 (1.4 %) mild events (nausea, headache, prurititis)
Barger [25] Kollé SP + AS 96 Most adverse events: headache, abdominal pain and respiratory symptoms.
   AQ + AS 100
   Placebo 98
Nankabirwa [26] Tororo SP 184 No severe adverse events.
Only mild (92 %) and moderate (8 %), with no difference between treatment groups
   SP + AQ 197
   DP 196
   Placebo 192
Nankabirwa [27] Tororo DP (monthly) 244 6 (2.5 %) severe adverse events Mild events were more frequent in the placebo group than the intervention arms
   DP (three to five monthly) 248 1 (0.40 %) death (due to acute lymphoblastic leukaemia); 5 (2 %) severe adverse events
   Placebo 248 3 (1.2 %) severe adverse events
  1. No number, SP sulfadoxine-pyrimethamine, SP + AQ sulfadoxine-pyrimethamine plus amodiaquine, SP + AS sulfadoxine-pyrimethamine plus artesunate, AQ + AS amodiaquine plus artesunate, DP dihydroartemisinin-piperaquine, % percentage